Moreover, as higher expression of the CTLA-4 gene is associated with good clinical outcome [38], application of CpG ODN that reduces the surface expression of CTLA-4 in leukaemic cells as a therapeutic agent may not be beneficial for CLL patients. This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.